

29 June 2026

BLS Pharmaceuticals Commences Trading Under New Name

- Company name officially changed from Bioxyne Limited to **BLS Pharmaceuticals Limited** following shareholder approval
- Shares will commence trading under the ASX code BLS from market open on 7 July 2026
- New corporate identity aligns with the Company's core pharmaceutical manufacturing and international commercial operations
- Rebrand reflects the growth of Breathe Life Sciences, Bioxyne's GMP licensed pharmaceutical manufacturing division
- BLS now operates one of Australia's most comprehensive regulated manufacturing platforms for medicinal cannabis, MDMA and psilocybin products
- New identity better reflects the Company's expanding international footprint across Australia, Europe, the United Kingdom and Japan

BLS Pharmaceuticals Limited ("BLS" or "the Company"), formerly Bioxyne Limited, is pleased to advise that following shareholder approval at the Company's General Meeting on 19 June 2026, the Australian Securities and Investments Commission has formally registered the Company's change of name to BLS Pharmaceuticals Limited.

The Company has commenced trading under its new name, which will be reflected together with the new ASX code (ASX:BLS), by the ASX from market open on 7 July 2026. Due to the share consolidation process underway the Company will trade until this date under the ASX code (ASX:BXNDA).

The rebrand reflects the significant growth of the business over recent years, including the growth of its wholly owned subsidiary Breathe Life Sciences into a global GMP pharmaceutical manufacturing, distribution and controlled substances platform.

Managing Director, Sam Watson said:

"This is more than a name change. It reflects the business we have built and the direction we are heading. Over the past several years, we have transformed the Company into an international pharmaceutical manufacturing and distribution business, with regulatory licences and capabilities that few companies globally possess.

Through Breathe Life Sciences, we have established a GMP manufacturing platform



supporting medicinal cannabis, MDMA, psilocybin and other regulated pharmaceutical products across multiple jurisdictions.

Adopting the BLS Pharmaceuticals name better aligns our corporate identity with our operations, our international growth strategy and the opportunities we see across emerging therapeutic markets. We believe the new name provides greater clarity for investors, customers and partners as we continue to expand our global pharmaceutical footprint.”

The BLS Pharmaceuticals brand aligns the Company more closely with its core operating business, Breathe Life Sciences, which has become a key driver of growth through its GMP manufacturing capabilities, international licences, proprietary Dr Watson® brand portfolio and expanding pharmaceutical supply agreements across Europe and other regulated markets.

The Company believes the new corporate identity more accurately reflects its position as a pharmaceutical manufacturer and global supplier of regulated therapeutic products.

The Company's new website is www.blspharma.com

Approved by the Board of BLS Pharmaceuticals Limited for release to the ASX.

For further information, please contact:

BLS Pharmaceuticals Limited

Sam Watson

Chief Executive Officer

sam@blspharma.com

NWR Communications

Melissa Tempira

Media & Investor Relations

melissa@nwrcommunications.com.au

About BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products.

BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (BLS) is a wholly owned subsidiary of BLS Pharmaceuticals Limited and a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA.

Established in 2018, BLS has developed an international pharmaceutical manufacturing and distribution platform with operations across Australia, Japan, the United Kingdom and Europe. The business specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing, international supply and the development of regulated therapeutic products.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. The Company owns the Dr Watson® brand portfolio across multiple international markets and supplies pharmaceutical products, active pharmaceutical ingredients and manufacturing services to customers globally.

In addition to its medicinal cannabis operations, BLS holds licences and capabilities supporting the manufacture, import, export and distribution of a range of regulated pharmaceutical products, positioning the business to participate in emerging therapeutic markets, including psychedelic medicines.

Corporate: blspharma.com

Australia: bls.com.au

International: breathelifesciences.com